Project Grant 2404627
Award Date
3/1/24
Completion Date
2/28/25
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Awardee
Duravax Inc. (PVNWZMVJ9T17)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Wilmington, NC 28409, USA
Similar Awards
The National Science Foundation awarded a $275,000 STTR Phase I grant to Inaedis, Inc. to develop an innovative method for the thermal stabilization of biopharmaceutical formulations. The project aims to establish a rapid room-temperature aerosol dehydration (RTAD) process that improves the stability of biologics, vaccines, and other pharmaceuticals, circumventing the need for a cold chain supply. This technology seeks to serve international markets by allowing the pharmaceutical industry to...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
The National Science Foundation (NSF) awarded a $274,980 SBIR Phase I Project Grant to Cisterna Biologics, Inc. to develop a novel platform for cost-efficient mRNA production in yeast. The project aims to transform yeast cells into efficient mRNA factories and utilize advanced chromatographic techniques for purification, with the goal of reducing mRNA manufacturing costs by 90% compared to current in vitro transcription methods. Key technical objectives include demonstrating stable mRNA fusion...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) grant award of $274,763 provides funding to Genexgen Inc., a small disadvantaged business, to develop an mRNA-based tolerogenic vaccine for viral-based gene therapies. The proposed solution aims to address the challenge of unwanted immune responses in cell and gene therapies, autoimmunity, and transplantation, which can limit the efficacy and accessibility of these treatments, particularly for rare...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
This $457,390 Project Grant award from the National Science Foundation's (NSF) Division of Materials Research aims to develop a new mRNA delivery system based on functional phosphoserine (PS) lipids. The award will support research to understand the targeted and immunomodulatory properties of these zwitterionic functional materials for mRNA delivery, with potential applications in gene therapy, protein-replacement therapy, and cancer immunotherapy. Key objectives include enhancing mRNA...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant awarded to Lyowave, Inc. will result in fundamental knowledge and new experimental methods needed to scale up the company's tunable high-frequency microwave heating technology for pharmaceutical and biologics manufacturing. The $304,436 award, effective March 1, 2025 through February 28, 2026, aims to address the scale-up challenge of using this technology for fast, uniform, volumetric...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant for $275,000 supports the development of a polymeric micelle platform to improve the solubility and stability of hydrophobic drugs. The key objectives are to: 1) optimize the formulation of spherical micelles for enhanced drug solubilization, 2) conduct initial toxicity studies to establish the safety of the platform, and 3) demonstrate the efficacy of the platform for solubilizing drug...